In April 2026, twelve peptides came off the FDA's Category 2 list. A great deal of the coverage treated that as a green light.
It was not a green light. It was the removal of a red light, on a road that still has no green light on it. Those twelve peptides did not move to the permitted category. They moved to no category at all — and most of them are still there.
This is the most consequential misunderstanding in the peptide space right now, and it predates the July vote by three months.
The category system, briefly
When substances are nominated for the 503A Bulks List, the FDA historically sorted them into three buckets:
| Category | Meaning | Can it be compounded? |
|---|---|---|
| Category 1 | Adequate support for inclusion; no significant safety concerns identified | Yes — subject to enforcement discretion |
| Category 2 | Sufficient information reviewed; significant safety risks identified | No |
| Category 3 | Inadequate information to assess | No |
Category 1 is the operative one. Substances there are subject to FDA enforcement discretion and may be used in compounding even though they are not technically on the official bulks list. Categories 2 and 3 got no such latitude.
One wrinkle: in 2025 the FDA issued guidance stating it would stop categorizing newly nominated substances, while Category 1 listings would continue to receive enforcement discretion. So the framework is partly vestigial — but the practical consequences of an existing listing still bite.
September 2023: the peptides go into Category 2
The FDA placed more than a dozen peptides into Category 2, citing significant safety concerns: risks related to immunogenicity, concerns about impurities, and the availability of only limited human clinical data.
The effect was immediate. Compounding pharmacies that had been preparing these peptides had to stop, or accept meaningful regulatory exposure. Much of the demand did not disappear — it migrated to research-chemical suppliers operating entirely outside the pharmacy system. That migration is the origin of the market as it exists today.
April 2026: twelve peptides leave Category 2
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that many Category 2 peptides would be considered for reclassification to Category 1. On April 15, 2026, he confirmed that twelve had been removed from Category 2 — following withdrawal of the nominations by the parties who originally submitted them.
The twelve: BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax, PEG-MGF, emideltide (DSIP), Epitalon, KPV, cathelicidin LL-37, and dihexa acetate.
The sentence that everything turns on
Removal from Category 2 does not automatically confer Category 1 status. There is no rule, no mechanism and no announcement that moved these substances into the permitted bucket. They left the restricted list and landed nowhere.
What “nowhere” means in practice
Recall the three conditions a bulk drug substance must satisfy for lawful 503A compounding: a USP or NF monograph, status as a component of an approved drug product, or presence on the 503A Bulks List.
A delisted peptide satisfies none of them. It is no longer formally designated a significant safety risk, which is a genuine change in the agency's stated position. But it has not acquired any affirmative permission. A pharmacy compounding it is still compounding a substance that does not meet any statutory condition.
One partial exception
GHK-Cu is the outlier. Non-injectable routes of GHK-Cu sit in Category 1 — the enforcement-discretion bucket — which is why topical copper-peptide formulations occupy different ground from everything else in this discussion. Injectable GHK-Cu is a separate question and is scheduled for review at the PCAC meeting to be held before the end of February 2027.
That route-based split is real and load-bearing. Same molecule, materially different regulatory posture depending on how it is delivered.
Why the delistings happened the way they did
The mechanism matters. These peptides were not removed because the FDA reassessed the science and reversed its safety findings. They were removed because the original nominators withdrew their nominations.
That is a procedural exit, not a scientific one. The agency's 2023 concerns — immunogenicity, impurities, thin clinical data — were never formally retracted. Indeed, FDA scientists raised substantially the same objections at the July 2026 meeting, recommending against all seven peptides under review.
Where this leaves buyers
The gray zone is not a loophole that legitimizes research-chemical purchases. Material sold as research-use-only is not a compounded prescription, is not dispensed by a licensed pharmacy, and is not subject to the characterization and sourcing standards a rulemaking would impose. Whatever happens to the 503A list, that distinction does not move.
State law does not track federal limbo
State boards of pharmacy have independent authority over compounding within their jurisdictions, and several have been considerably more direct than the FDA.
Ohio is the clearest example. Its Board of Pharmacy has issued guidance addressing common prescriber-clinic and medical-spa violations, stating explicitly that peptides in Category 2 or Category 3 cannot be compounded and that doing so violates state law. The board has backed this with enforcement actions — including, in some cases, summary suspension — against pharmacies compounding substances such as BPC-157, CJC-1295/ipamorelin and kisspeptin.
Other states have taken different approaches. How any of them will respond to the July PCAC recommendations is unresolved. A federal rule would not automatically override a stricter state standard.
How to read a status claim
Given all of the above, a practical filter for any statement about a peptide's legal status:
- “Removed from Category 2” — accurate for the twelve, and means less than it sounds like.
- “Now Category 1” — false for eleven of the twelve. True only for non-injectable GHK-Cu.
- “On the 503A Bulks List” — false for all twelve. Requires completed rulemaking.
- “FDA approved” — false, and a different process entirely. No peptide in this group is an approved drug.
- “Legal to compound” — false as of today for all of them.
The gray zone in one paragraph
Twelve peptides left the restricted list in April 2026 because their nominations were withdrawn, not because the FDA reversed its safety assessment. Leaving Category 2 conferred no permission. Eleven of the twelve remain in a space with no affirmative legal basis for compounding, and non-injectable GHK-Cu is the lone partial exception. Only completed rulemaking — or an explicit interim enforcement-discretion signal — changes that.
Common questions
No. Leaving Category 2 removes a formal safety designation but grants nothing. Lawful 503A compounding requires a USP/NF monograph, component status in an approved drug, or presence on the 503A Bulks List. Delisting supplies none of those.
Non-injectable GHK-Cu sits in Category 1, which carries enforcement discretion. Injectable GHK-Cu does not, and is scheduled for PCAC review before the end of February 2027. The route of administration is what separates them.
No. The twelve came off Category 2 because the original nominators withdrew their nominations — a procedural exit. The agency's 2023 concerns were not retracted, and FDA scientists raised similar objections again at the July 2026 meeting.
Yes. State boards of pharmacy set their own standards and can be stricter than the federal baseline. Ohio has issued explicit guidance prohibiting compounding of Category 2 and 3 peptides and has taken enforcement action on that basis.
It does not. Research-use-only material sits outside the pharmacy system entirely — no prescription, no licensed dispensing, and none of the sourcing or characterization requirements that a compounding rule would impose. That is a separate category from anything the 503A discussion covers.
Sources
- US Food and Drug Administration. “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Docket FDA-2026-N-2979. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” Client alert, July 27, 2026.
- Holland & Knight. “FDA Advisory Committee Endorses Compounding of Certain Peptides.” August 2026.
- Latham & Watkins. “FDA on Peptides: A New Landscape for Compounders.” 2026.
- Buchanan Ingersoll & Rooney PC. “FDA PCAC Recommends Six Peptides for the 503A Bulks List.” 2026.
- Sheppard Mullin. “What to Watch: Status Update on Peptide Regulation.” June 2026.